270 related articles for article (PubMed ID: 23190608)
1. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N; Di Martino MT; Foresta U; Leone E; Lionetti M; Leotta M; Gullà AM; Pitari MR; Conforti F; Rossi M; Agosti V; Fulciniti M; Misso G; Morabito F; Ferrarini M; Neri A; Caraglia M; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Cell Death Dis; 2012 Nov; 3(11):e436. PubMed ID: 23190608
[TBL] [Abstract][Full Text] [Related]
2. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
3. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
5. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.
Amodio N; Bellizzi D; Leotta M; Raimondi L; Biamonte L; D'Aquila P; Di Martino MT; Calimeri T; Rossi M; Lionetti M; Leone E; Passarino G; Neri A; Giordano A; Tagliaferri P; Tassone P
Cell Cycle; 2013 Dec; 12(23):3650-62. PubMed ID: 24091729
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway.
Zeng K; Wang Y; Yang N; Wang D; Li S; Ming J; Wang J; Yu X; Song Y; Zhou X; Deng B; Wu X; Huang L; Yang Y
Mol Neurobiol; 2017 Aug; 54(6):4000-4014. PubMed ID: 27311771
[TBL] [Abstract][Full Text] [Related]
7. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
Fulciniti M; Amodio N; Bandi RL; Cagnetta A; Samur MK; Acharya C; Prabhala R; D'Aquila P; Bellizzi D; Passarino G; Adamia S; Neri A; Hunter ZR; Treon SP; Anderson KC; Tassone P; Munshi NC
Blood Cancer J; 2016 Jan; 6(1):e380. PubMed ID: 26771806
[TBL] [Abstract][Full Text] [Related]
8. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
10. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
[TBL] [Abstract][Full Text] [Related]
11. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
13. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
[TBL] [Abstract][Full Text] [Related]
14. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
[TBL] [Abstract][Full Text] [Related]
16. miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1.
Wang H; Ding Q; Wang M; Guo M; Zhao Q
Hematology; 2019 Dec; 24(1):32-38. PubMed ID: 30068241
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]